📢New from our 12-year Ono-WCNDD collab: a best-in-class in vivo tool compound for TREK channels—first POC for activators as non-opioid analgesics & inhibitors as pro-cognitive agents. Already among the most read! 🔗 pubs.acs.org/doi/10.1021/ac… #GoodTuesday #research Vanderbilt University

🌟 Staff Spotlight: Elizabeth Childress, Drug Discovery Scientist I at WCNDD! From high-throughput screening to mentoring, Elizabeth’s work fuels translational neuroscience at Vanderbilt. 🧠💊 🔗 Read more: bit.ly/4jxU3qB #DrugDiscovery #Neuroscience #Vanderbilt #STEM

Have you seen our latest newsletter? 📰 Catch up on recent news, new patents, and what’s happening at WCNDD. 📩 Read it: lnkd.in/ew7iGgzY 🧠 Subscribe: bit.ly/3GSigJG #vanderbilt #neuroscience #research #innovation

🚨 New publications from WCNDD! Our latest research advances understanding & treatment of neurodegenerative diseases. 🔬 Alzheimer’s, neuroinflammation, and more—check it out! 📚 linktr.ee/wcnddtn #Neuroscience #DrugDiscovery #Alzheimers #Research #vanderbilt

Vanderbilt has awarded over $10M in internal grants since 2021 to accelerate high-impact research across disciplines—from AI in medicine to gene therapies. 💡🔬 Read how programs like Seeding Success are changing the game: 🔗 news.vanderbilt.edu/2025/05/12/the…

🚨 #NEW from the Warren Center! We report a selective M4 muscarinic receptor antagonist with potential in treating movement disorders. Read in ACS Chem Neurosci: pubs.acs.org/doi/10.1021/ac… Congrats to the WCNDD team, along with our collaborators! #research #vanderbilt

Hear about groundbreaking research that could change how we treat neurodegenerative diseases and chronic pain on the #QuantumPotential podcast with VU Provost Office and Craig Lindsley, executive director of WCNDD (Vanderbilt School of Medicine Basic Sciences). Listen wherever you get your podcasts! 🎧🎙️

New research from the Warren Center shows how academic-industry partnerships can accelerate drug discovery! Learn how the TREK channel program is advancing neuroscience therapeutics. 🧠💊 🔗 Read more: medschool.vanderbilt.edu/basic-sciences… #DrugDiscovery #Neuroscience #Vanderbilt #research

After more than a decade of collaboration, researchers from Vanderbilt University WCNDD and Japan’s Ono Pharmaceutical have delivered a powerful proof-of-concept: first-in-class TREK channel modulators with applications in pain relief. Learn more 👉 medschool.vanderbilt.edu/basic-sciences…

🎉 The Warren Center is celebrating 5 years of innovation in neuroscience drug discovery! Huge thanks to the William K. Warren Foundation for making our mission possible. Here's to advancing brain health, together. 🧠💊 Vanderbilt University Vanderbilt School of Medicine Basic Sciences Vanderbilt CTTC

🔬 #New from WCNDD: Our latest publication in ACS Med Chem Lett reports novel M1 positive allosteric modulators with strong potency and DMPK profiles—highlighting a new scaffold for CNS drug discovery. Read here: pubs.acs.org/doi/10.1021/ac… 🧪 DOI: 10.1021/acsmedchemlett.5c00271

Vanderbilt was recently ranked among the 30 most beautiful college campuses in the U.S. by Travel + Leisure! "With some 190 species of trees scattered across 300-plus acres... it's easy to forget you're actually in the middle of a city." Learn more: vu.edu/uj1vr

The Vanderbilt Board of Trust has reappointed VU Provost Office C. Cybele Raver to continue leading Vanderbilt’s academic mission through 2031, ensuring long-term continuity and strategic execution through the next decade. news.vanderbilt.edu/2025/06/18/van…

🎉 Thanks to all who joined us to celebrate 5 years of the Warren Center for Neuroscience Drug Discovery! We’re proud of the progress made—and grateful to the William K. Warren Foundation for making it possible. Here’s to the next 5! 🧠✨ #Neuroscience #DrugDiscovery #Research

Meet Srinivasan Krishnan, one of our incredible Drug Discovery Scientists here at WCNDD. Learn more about his journey, expertise, and what fuels his passion for science. 👉 Read the full spotlight: lab.vanderbilt.edu/lindsleylab/20…

.WCNDD recently celebrated the five-year anniversary of its endowment and creation — a milestone made possible by the visionary support of the 𝑾𝒊𝒍𝒍𝒊𝒂𝒎 𝑲. 𝑾𝒂𝒓𝒓𝒆𝒏 𝑭𝒐𝒖𝒏𝒅𝒂𝒕𝒊𝒐𝒏!

🧠 New publication alert! WCNDD’s first-in-human study of VU0467319, a selective M1 muscarinic receptor PAM, shows it’s safe, well-tolerated, and engages its target — a promising step for Alzheimer’s disease therapeutics. 📄 Read more: alzres.biomedcentral.com/articles/10.11…

We’re proud to share that NMRA-861, a muscarinic M4 PAM discovered at WCNDD, has entered Phase 1 trials with Neumora. 🧠 “A potential best-in-class therapy offering hope for patients with schizophrenia.” – Dr. Craig Lindsley 🔗 ir.neumoratx.com/news-releases/…

🌟 Meet Sheila Elder, an administrative officer for the WCNDD whose dedication make research and operations run smoothly behind the scenes. A fun fact about her? "It has been scientifically proven that I make the best banana pudding in the world." 🍌 medschool.vanderbilt.edu/basic-sciences…

Congratulations to Neumora and the Warren Center for Neuroscience Drug Discovery team for this exciting update! Read the full press release: cttc.co/article/202507…